ArticleNeurology and therapy2025

Persistence to Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis: Results from the German NeuroTransData Registry.

Stefan Braune et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.